REVANCE THERAPEUTICS, INC. (NASDAQ:RVNC) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
ITEM 5.02>DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION
OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY
ARRANGEMENTS OF CERTAIN OFFICERS
Directors (the Board) of Revance Therapeutics, Inc. (the
Company), tendered his resignation from the Board, including from
its Audit Committee, effective on May 11, 2017. Mr. Prygocki
resigned from the Board to pursue a new business venture. His
decision did not involve any disagreement with the Company, its
management or the Board. On May 11, 2017, the Board: (1)
designated Robert Byrnes, an existing member of the Audit
Committee, as Chairman of the Audit Committee, and (2) appointed
Angus C. Russell, the Companys Chairman of the Board, as a member
of the Audit Committee.
11, 2017, the stockholders voted on the two proposals listed
below. The proposals are described in detail in the Companys
definitive proxy statement for the 2017 annual meeting, filed
with the Securities and Exchange Commission on March 24, 2017.
The results of the matters voted upon at the meeting were:
|
a)
|
Each of the Class III nominees of the Companys Board of
Directors was elected to hold office until the Companys 2020 annual meeting of stockholders. The Class III nominees were: L. Daniel Browne; 22,448,903 shares of Common Stock voted for, and 2,149,245 withheld; Robert Byrnes; 22,104,007 shares of Common Stock voted for, and 2,494,141 withheld; and Philip J. Vickers, Ph.D.; 22,423,991 shares of Common Stock voted for, and 2,174,157 withheld; and 3,373,151 shares of Common Stock broker non-votes for all directors. The terms of office of Class I directors Angus C. Russell, Julian S. Gangolli, and Phyllis Gardner, M.D. continue until the Companys 2018 annual meeting of stockholders. The term of office of Class II director Ronald W. Eastman continues until the Companys 2019 annual meeting of stockholders. |
|
b)
|
The stockholders ratified the selection by the Companys
Board of Directors of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2017: 27,784,970 shares of Common Stock voted for, 90,457 against, 95,872 abstaining, and no broker non-votes. |
About REVANCE THERAPEUTICS, INC. (NASDAQ:RVNC)
Revance Therapeutics, Inc. is a biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its TransMTS technology enables delivery of botulinum toxin type A through investigational drug product candidates, including DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical, and DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable. Its botulinum toxin-peptide complex has over two components that contribute to the performance of RT001 and RT002. Its TransMTS peptide provides the delivery across the skin and restricts the toxin molecule to the target site. Then, the botulinum toxin type A provides the mechanism of pharmacologic action and is responsible for the drug effects demonstrated in its clinical trials. Its TransMTS peptide technology serves various purposes depending on whether it is used in a topical formulation or in an injectable formulation. REVANCE THERAPEUTICS, INC. (NASDAQ:RVNC) Recent Trading Information
REVANCE THERAPEUTICS, INC. (NASDAQ:RVNC) closed its last trading session down -0.75 at 20.15 with 192,162 shares trading hands.
